Short antisense oligonucleotide-mediated inhibition is strongly dependent on oligo length and concentration but almost independent of location of the target sequence.
The inhibitory effect of short antisense oligodeoxynucleotides (aODNs) on cRNA expression in Xenopus oocytes was measured using an electrophysiological assay based on subunit-specific block of cloned alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors. The effect of both phosphorothioate-modified (PS) and phosphodiester (PO) aODNs was strongly length dependent with a half-maximal inhibition calculated for an oligo length of 7.6 nucleotides (nt) and 9.9 nt, respectively. More than 95% inhibition was mediated by a PS aODN of 12 nt and by PO aODNs > or = 15 nt. At a given length PS and PO aODNs showed differential dependence of their inhibitory effect on the injected aODN concentration (half-maximal inhibition at 18 ng/microliter for a PO 12-mer and at 0.19 ng/microliter for a PS 12-mer) and differential saturation behavior. The inhibitory effect of aODNs, even as short as 8 nt for PS oligomers, was highly sequence specific, but almost independent of the position of the respective target site on the cRNA (for PS 8-mers, > or = 70% expression inhibition throughout the tested target sites from the translation initiation to the 3'-untranslated region). Thus, short PS aODNs can be reliably used in order to specifically inhibit protein expression in experiments addressing physiological, molecular biological, and perhaps even therapeutical issues.
Fakler
B
B
Sektion für Sensorische Biophysik, HNO-Universitätsklinik Tübingen, Germany.
Herlitze
S
S
Amthor
B
B
Zenner
H P
HP
Ruppersberg
J P
JP
D000818:Animals; D001483:Base Sequence; D016373:DNA, Antisense / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004553:Electric Conductivity; D007210:Indoleacetic Acids; D008969:Molecular Sequence Data; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D009865:Oocytes; D010648:Phenylacetates / Q000494:pharmacology; D011073:Polyamines / Q000494:pharmacology; D014176:Protein Biosynthesis / Q000187:drug effects*; D018075:RNA, Complementary; D018091:Receptors, AMPA / Q000145:classification / Q000235:genetics*; D013329:Structure-Activity Relationship; D013873:Thionucleotides; D014981:Xenopus / Q000235:genetics
D016373:DNA, Antisense; D007210:Indoleacetic Acids; D016376:Oligonucleotides, Antisense; D010648:Phenylacetates; D011073:Polyamines; D018075:RNA, Complementary; D018091:Receptors, AMPA; D013873:Thionucleotides; C558368:argiotoxin-636